The Technical Analyst
Singular Genomics [OMIC]
Exchange: NASDAQ Global Select Sector: Healthcare Industry: Medical - Instruments & Supplies
Singular Genomics Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.90% $0.404
/ 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 29.95 mill |
| EPS: | -1.300 |
| P/E: | -0.310 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 74.09 mill |
| Avg Daily Volume: | 0.114 mill |
| RATING 2024-04-26 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.310 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.310 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.362 - 0.440 ( +/- 9.74%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-15 | Ropp Sam | Sell | 4 187 | Restricted Stock Units |
| 2024-03-15 | Ropp Sam | Buy | 4 187 | Common Stock |
| 2024-03-15 | Meeter Dalen | Buy | 6 250 | Common Stock |
| 2024-03-15 | Meeter Dalen | Sell | 6 250 | Restricted Stock Units |
| 2024-03-15 | Glezer Eli N. | Buy | 7 500 | Common Stock |
| INSIDER POWER |
|---|
| 41.22 |
| Last 98 transactions |
| Buy: 7 010 444 | Sell: 2 326 610 |
Forecast:
16:00 - $0.401
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.401
Forecast 2: 16:00 - $0.401
Forecast 3: 16:00 - $0.401
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.404 (0.90% ) |
| Volume | 0.106 mill |
| Avg. Vol. | 0.114 mill |
| % of Avg. Vol | 92.59 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OMIC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
OMIC
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.
Last 10 Buy Signals
Latest Press Releases
2024-03-18 16:05:00 - Press Release
Singular Genomics Reports Recent Highlights And Fourth Quarter And Full Year 2023 Financial Results
San diego, march 18, 2024 (globe newswire) -- singular genomics systems, inc. (nasdaq: omic), a company leveraging novel next-generation sequencing (ngs) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the fourth quarter and full year ended december 31, 2023.
2024-03-04 16:05:00 - Press Release
Singular Genomics To Report Fourth Quarter And Full Year 2023 Financial Results On March 18, 2024
San diego, march 04, 2024 (globe newswire) -- singular genomics systems, inc. (nasdaq: omic), a company leveraging novel next-generation sequencing (ngs) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter and full year ended december 31, 2023 after the market close on monday, march 18, 2024. the company's management will discuss the results during a conference call beginning at 1:30 p.m. pacific time / 4:30 p.m. eastern time.
2024-02-05 10:55:00 - Press Release
Singular Genomics Showcases New G4x™ Spatial Sequencer At Agbt And Announces Significant Advances In Throughput, Quality, And Usability For G4® Sequencing Platform
San diego, feb. 05, 2024 (globe newswire) -- singular genomics systems, inc. (nasdaq: omic), a company leveraging novel next-generation sequencing (ngs) and spatial multiomics technologies to empower researchers and clinicians, announced groundbreaking new products and capabilities at the advances of genome biology and technology (agbt) conference in orlando, florida.
2024-02-05 10:54:00 - Press Release
Singular Genomics Unveils G4x™ Spatial Sequencer, Transforming The Landscape Of In Situ Multiomic Analysis
San diego, feb. 05, 2024 (globe newswire) -- singular genomics systems, inc. (nasdaq: omic), a company leveraging novel next-generation sequencing (ngs) and spatial multiomics technologies to empower researchers and clinicians, today unveiled the g4x™ spatial sequencer. the g4x is designed to offer high-throughput in situ direct sequencing of rna (direct-seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (ffpe) tissues. the g4x will share the same platform as the existing g4® sequencer and is expected to be the industry's first dual-purpose instrument offering both traditional ngs and tissue-based spatial sequencing capabilities. with the addition of high-throughput multiomics and novel direct-seq technology to its portfolio with the g4x, singular is positioned to become the only company worldwide to offer in situ spatial sequencing of tissues and ngs on the same instrument.
2024-01-07 17:00:00 - Press Release
Singular Genomics Reports Instrument Shipments And Preliminary Unaudited Fourth Quarter 2023 Revenue
San diego, jan. 07, 2024 (globe newswire) -- singular genomics systems, inc. (nasdaq: omic), a company leveraging novel next-generation sequencing (ngs) and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and preliminary unaudited revenue for the fourth quarter of 2023.
Latest News
2024-03-04 16:05:00 - GlobeNewsWire
Singular Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Monday, March 18, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
2023-11-14 21:10:03 - Seeking Alpha
Singular Genomics Systems, Inc. (OMIC) Q3 2023 Earnings Call Transcript
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - CEO, Founder & Chairman Dalen Meeter - CFO Conference Call Participants Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs John Sourbeer - UBS Operator Greetings. Welcome to the Singular Genomics Systems, Inc. Third Quarter 2023 Earnings Conference Call.
2023-10-24 16:22:00 - GlobeNewsWire
Singular Genomics to Report Third Quarter 2023 Financial Results on November 14, 2023
SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2023 after the market close on Tuesday, November 14, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
2023-09-20 11:28:22 - InvestorPlace
Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now
The biotech sector never fails to offer up stocks full of massive issues at any given time. Developing novel therapeutic devices and pharmaceuticals is, after all, very expensive.
2023-09-08 08:00:00 - GlobeNewsWire
Singular Genomics to Present at the Gilmartin Group Emerging Growth Company Showcase
SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to participate in the virtual Gilmartin Group Emerging Growth Company Showcase.
2023-08-09 20:27:13 - Seeking Alpha
Singular Genomics Systems, Inc. (OMIC) Q2 2023 Earnings Call Transcript
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder, Chair and CEO Dalen Meeter - CFO Conference Call Participants Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Operator Good day, everyone, and welcome to the Singular Genomics Systems, Inc. Second Quarter 2023 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation.
2023-07-26 16:05:00 - GlobeNewsWire
Singular Genomics to Report Second Quarter 2023 Financial Results on August 9, 2023
SAN DIEGO, July 26, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter 2023 after the market close on Wednesday, August 9, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
2023-06-01 16:05:00 - GlobeNewsWire
Singular Genomics to Present at the Goldman Sachs Global Healthcare Conference
SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA.
2023-05-13 18:28:02 - Seeking Alpha
Singular Genomics Systems, Inc. (OMIC) Q1 2023 Earnings Call Transcript
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder and CEO Dalen Meeter - CFO Conference Call Participants Tom Stevens - TD Cowen John Sourbeer - UBS Michael Ryskin - Bank of America Operator Greetings. Welcome to the Singular Genomics Systems, Incorporated First Quarter 2023 Earnings Conference Call.
2023-05-09 19:07:24 - Zacks Investment Research
Similar Genomics Systems (OMIC) Reports Q1 Loss, Lags Revenue Estimates
Similar Genomics Systems (OMIC) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.31 per share a year ago.